Clinical Trials
462
Active:368
Completed:89
Trial Phases
4 Phases
Phase 1:240
Phase 2:13
Phase 3:14
+1 more phases
Drug Approvals
37
NMPA:29
EMA:8
Drug Approvals
Enfortumab Vedotin for Injection
- Product Name
- 备思复
- Approval Number
- 国药准字SJ20240034
- Approval Date
- Aug 13, 2024
NMPA
Enfortumab Vedotin for Injection
- Product Name
- 备思复
- Approval Number
- 国药准字SJ20240035
- Approval Date
- Aug 13, 2024
NMPA
Tacrolimus Sustained-release Capsules
- Product Name
- 他克莫司缓释胶囊
- Approval Number
- 国药准字HJ20150031
- Approval Date
- Jul 10, 2024
NMPA
Tacrolimus Sustained-release Capsules
- Product Name
- 他克莫司缓释胶囊
- Approval Number
- 国药准字HJ20150029
- Approval Date
- Jul 10, 2024
NMPA
Solifenacin Succinate Tablets
- Product Name
- 卫喜康
- Approval Number
- 国药准字HJ20140209
- Approval Date
- May 29, 2023
NMPA
Mirabegron Sustained-release Tablets
- Product Name
- 贝坦利
- Approval Number
- 国药准字HJ20171298
- Approval Date
- Mar 15, 2022
NMPA
Mirabegron Sustained-release Tablets
- Product Name
- 贝坦利
- Approval Number
- 国药准字HJ20171299
- Approval Date
- Mar 15, 2022
NMPA
Mirabegron Sustained-release Tablets
- Product Name
- 贝坦利
- Approval Number
- 国药准字HJ20171305
- Approval Date
- Mar 15, 2022
NMPA
- Prev
- 1
- 2
- 3
- Next
Clinical Trials
Distribution across different clinical trial phases (270 trials with phase data)• Click on a phase to view related trials
Phase 1
240 (88.9%)Phase 3
14 (5.2%)Phase 2
13 (4.8%)Phase 4
3 (1.1%)A Study of MA-0217 (ASP1128) in Healthy Adult Subjects and Healthy Elderly Subjects
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 102
- Registration Number
- NCT04742517
- Locations
- 🇺🇸
Parexel Early Phase Clinical Unit - Los Angeles, Glendale, California, United States
A Study of ASP8302 in Participants With Underactive Bladder
- First Posted Date
- 2018-10-11
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 135
- Registration Number
- NCT03702777
- Locations
- 🇩🇪
Site DE49001, Duisburg, Germany
🇩🇪Site DE49002, Duisburg, Germany
🇩🇪Site DE49004, Gronau, Germany
A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis
Phase 2
Completed
- Conditions
- Bladder Pain SyndromeInterstitial Cystitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-09-13
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 119
- Registration Number
- NCT03282318
- Locations
- 🇧🇪
Site BE32001, Leuven, Belgium
🇨🇿Site CZ42002, Plzen, Czechia
🇩🇪Site DE49003, Duisburg, Germany
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP7713 in Healthy Non-Japanese Adult and Elderly Subjects and Healthy Japanese Adult Subjects
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 40
- Registration Number
- NCT03108755
- Locations
- 🇬🇧
Site GB44001, Harrow, Middlesex, United Kingdom
A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function
- First Posted Date
- 2016-11-16
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 34
- Registration Number
- NCT02965040
- Locations
- 🇩🇪
Site DE49001, Munchen, Germany
🇬🇧Site GB44001, Liverpool, United Kingdom
- Prev
- 1
- 2
- 3
- 4
- 5
- 19
- Next
News
No news found